Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Arrowhead Pharmaceuticals (ARWR) Stock Price & Analysis
1,388 Followers
ARWR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.67 - $39.83
Previous Close$26.05
Volume806.44K
Average Volume (3M)1.06M
Market Cap
$3.24B
Enterprise Value$2.97B
Total Cash (Recent Filing)$395.41M
Total Debt (Recent Filing)$118.92M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 05, 2024EPS Estimate
-$0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.24
Shares Outstanding124,200,230
10 Day Avg. Volume1,257,028
30 Day Avg. Volume1,056,483
Standard Deviation0.20
R-Squared0.06
Alpha0.00514
Financial Highlights & Ratios
Price to Book (P/B)6.68
Price to Sales (P/S)13.16
Price to Cash Flow (P/CF)-8.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue83.74
Enterprise Value/Gross Profit12.34
Enterprise Value/Ebitda-6.81
Forecast
1Y Price Target
$48.70Price Target Upside93.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Arrowhead Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Ph3 PALISADE study of plozasiran in familial chylomicronemia syndrome met its primary endpoint, achieving significant median reductions in triglycerides.
Drug EfficacyTreatment with plozasiran achieved up to 80% triglyceride lowering at 10 months with 25mg and 50mg quarterly doses.
Pipeline DevelopmentArrowhead continues to advance its muscle-targeted pipeline, which though early-stage, may soon shine and unlock substantial value for shareholders.
Bears Say
Clinical Development RisksRisks include clinical development risk, competitor risk, novel modality risk, commercialization risk, reimbursement risk, pricing risk, business development risk, capital market and dilution risk, and disruptions to clinical trials owing to the war in Eastern Europe.
Financial PerformanceARWR remains engaged with FDA and potential strategic financing partners to resolve balance sheet overhang, which also drove 11/30 sell-off (-25%) and PT lowering from $60 to $50.
Program ViabilityEnded development of preclinical program ARO-SOD1 and partnered HZN-457 due to a lack of commercial viability.
---
Ownership Overview
9.12% Insiders
23.54% Mutual Funds
47.94% Other Institutional Investors
19.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $20.67 and its highest was $39.83 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Currently, no data Available
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Aug 05, 2024 which is in 33 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.472 by -$0.548.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -$0.53.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 124,200,230 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.472. Following the earnings report the stock price went down -10.68%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 118M.
---
Arrowhead Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$48.70 (93.10% Upside)
$48.70 (93.10% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $168.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.94%
12-Months-Change
Fundamentals
Return on Equity
-101.18%
Trailing 12-Months
Asset Growth
7.16%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
ARWR Earnings Call
Q2 2024
0:00 / 0:00
---
ARWR Stock 12 Month Forecast
Average Price Target
$48.70
▲(93.10% Upside)
Technical Analysis
Best Analysts Covering ARWR
1 Year
1 Year Success Rate
20/36 ratings generated profit
1 Year Average Return
+36.89%
reiterated a buy rating last month
Copying Keay Nakae's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +36.89% per trade.
---